Minerva Neurosciences Inc (NERV)
2.60
+0.26
(+11.11%)
USD |
NASDAQ |
May 07, 16:00
Minerva Neurosciences Total Liabilities (Quarterly): 87.10M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 87.10M |
| December 31, 2023 | 85.36M |
| September 30, 2023 | 83.18M |
| June 30, 2023 | 79.65M |
| March 31, 2023 | 78.21M |
| December 31, 2022 | 75.11M |
| September 30, 2022 | 74.00M |
| June 30, 2022 | 73.34M |
| March 31, 2022 | 71.35M |
| December 31, 2021 | 69.15M |
| September 30, 2021 | 69.48M |
| June 30, 2021 | 69.16M |
| March 31, 2021 | 66.46M |
| December 31, 2020 | 4.964M |
| September 30, 2020 | 7.198M |
| June 30, 2020 | 9.223M |
| March 31, 2020 | 50.16M |
| December 31, 2019 | 49.72M |
| September 30, 2019 | 55.29M |
| June 30, 2019 | 53.02M |
| March 31, 2019 | 52.38M |
| Date | Value |
|---|---|
| December 31, 2018 | 48.87M |
| September 30, 2018 | 49.13M |
| June 30, 2018 | 50.28M |
| March 31, 2018 | 53.18M |
| December 31, 2017 | 52.10M |
| September 30, 2017 | 63.33M |
| June 30, 2017 | 29.35M |
| March 31, 2017 | 29.02M |
| December 31, 2016 | 26.96M |
| September 30, 2016 | 28.58M |
| June 30, 2016 | 25.90M |
| March 31, 2016 | 27.78M |
| December 31, 2015 | 27.26M |
| September 30, 2015 | 26.25M |
| June 30, 2015 | 25.95M |
| March 31, 2015 | 27.41M |
| December 31, 2014 | 16.95M |
| September 30, 2014 | 16.61M |
| June 30, 2014 | 23.72M |
| March 31, 2014 | 19.05M |
| December 31, 2013 | 8.995M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.964M
Minimum
Dec 2020
87.10M
Maximum
Mar 2024
60.56M
Average
69.32M
Median
Total Liabilities (Quarterly) Benchmarks
| Viking Therapeutics Inc | 33.63M |
| Janux Therapeutics Inc | 36.06M |
| ACADIA Pharmaceuticals Inc | 317.20M |
| Karyopharm Therapeutics Inc | 376.64M |
| Calidi Biotherapeutics Inc | 18.25M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 50.51M |
| Shareholders Equity (Quarterly) | -36.59M |